Skip to main content
. Author manuscript; available in PMC: 2018 Jan 8.
Published in final edited form as: Cell Rep. 2017 Jul 5;20(1):224–235. doi: 10.1016/j.celrep.2017.05.070

Figure 5. S-Glutathionylation of Cys188 Is Required for Maintaining IL-1β Bioactivity In Vivo.

Figure 5

(A) Kaplan-Meier survival curves indicate that mutant IL-1β (188C/S) has higher bioactivity than WT IL-1β. The bioactivities of i.p.-injected WT and mutant IL-IL-1β (188C/S) have higher bioactivity than WT IL-1β. The bioactivities of i.p.-injected WT and mutant IL-1β were assessed at two doses: 0.5 μg/mouse and 0.2 μg/mouse. *p ≤ 0.005 versus WT IL-1β, log-rank test.

(B) The effect of Grx1 on cysteine modification of IL-1β analyzed by MS. His-tagged recombinant mouse IL-1β (1 μg) and recombinant Grx1 (1 μg) were injected i.p. into WT mice. Whole-body γ-irradiation was conducted 24 hr after injection. Recombinant IL-1β was pulled down from serum using Ni-NTA agarose beads 3 days after injection, separated by SDS-PAGE, and then processed for MS. Representative graphs for each indicated modification are shown.

(C) Kaplan-Meier survival curves showing that co-injection of Grx1 reduces WT IL-1β, but not mutant IL-1β (188C/S), bioactivity. *p ≤ 0.005 versus IL-1β (WT or mutant form) alone, log-rank test. n.s., not significant.